Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Renal Cell Cancer (RCC) after Sunitinib Failure

PURPOSE: This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib. MATERIALS AND METHODS: This open-label, multicenter, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients who had prior nephr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tannir, Nizar M., Wong, Yu-Ning, Kollmannsberger, Christian K., Ernstoff, Marc S., Perry, David J., Appleman, Leonard J., Posadas, Edwin M., Cho, Daniel, Choueiri, Toni K., Coates, Andrew, Gupta, Neeraj, Pradhan, Rajendra, Qian, Jiang, Chen, Jihong, Scappaticci, Frank A., Ricker, Justin L., Carlson, Dawn M., Michaelson, M. Dror
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4167844/
https://ncbi.nlm.nih.gov/pubmed/22078932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2011.09.002
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items